RxDoctor Payments Data

James Clarke, MD

Cardiovascular Disease · Towson, MDNPI 1215938832

Payments from drug & device makers

$3,026in general payments, 2019–2025

Across 170 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$777
  • Boehringer Ingelheim$605
  • Novartis$465
  • Johnson & Johnson$290
  • Sanofi-aventis U.S. LLC$214
  • Pfizer$189
  • plus $486 from 9 others

What the payments were for

  • Food & beverage$3,019100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,026 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$309,505
Medicare patients
327
Services billed
2,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$113,355
EntrestoSacubitril/Valsartan35$52,475
JardianceEmpagliflozin16$28,552
MultaqDronedarone Hcl13$22,819
Clonidine54$9,972
NexlizetBempedoic Acid/Ezetimibe13$5,464
Ranolazine ErRanolazine26$3,613
Ezetimibe85$3,527
Metoprolol Succinate223$3,487
Losartan Potassium223$3,146
Amlodipine Besylate279$2,828
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,635
ClopidogrelClopidogrel Bisulfate106$1,335
Flecainide Acetate22$1,214
Lisinopril84$987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$189$113,35590 claims
NovartisEntresto$465$52,47535 claims
Boehringer IngelheimJardiance$605$28,55216 claims
Sanofi-aventis U.S. LLCMultaq$214$22,81913 claims
Esperion Therapeutics, Inc.Nexlizet$777$5,46413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →